efgartigimod (Vyvgart) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA First in Class Fast Track FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( hyaluronidase (human recombinant) (Hylenex), efgartigimod (Vyvgart) - other name: efgartigimod alfa and hyaluronidase-qvfc )

Alternative names

argx-113

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Myasthenia Gravis (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Cardiomyopathies (Phase 2/Phase 3)

Glomerulonephritis, Membranous (Phase 2)

Guillain-Barre Syndrome (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Lupus Nephritis (Phase 2)

Myasthenia Gravis (Phase 3)

Myositis (Phase 3)

Pemphigoid, Bullous (Phase 3)

Pemphigus (Phase 3)

Pharmacology (Phase 1)

Polyradiculoneuropathy (Phase 2)

Postural Orthostatic Tachycardia Syndrome (Phase 2)

Sjogren's Syndrome (Phase 2)

Therapeutic Equivalency (Phase 1)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue